Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3 Pt 1
|
| pubmed:dateCreated |
1996-10-24
|
| pubmed:abstractText |
We examined two recently described cytokeratin markers, CYFRA 21-1 (cytokeratin fragment recognized by KS 19-1 and BM 19-21 antibodies) and TPS (specific M3 epitope of the tissue polypeptide antigen), in 405 lung cancer patients (91 small-cell and 314 non-small-cell lung cancers) and 59 patients presenting with nonmalignant pulmonary disease. Sensitivity-specificity relationship, as analyzed by receiver operating characteristic curves, demonstrated a higher accuracy of CYFRA 21-1 in comparison with TPS in both small-cell and non-small-cell lung cancers. Thresholds of 3.6 ng/ml and 140 U/L for CYFRA 21-1 and TPS respectively gave a 90% to 95% specificity. Sensitivity of CYFRA 21-1 was the highest in squamous-cell carcinomas (0.61) and the lowest in small-cell lung cancers (0.36), whereas sensitivity of TPS did not vary significantly according to histology (overall sensitivity, 0.40). In non-small-cell lung cancers, both serum CYFRA 21-1 and serum TPS distributions varied significantly according to Mountain's stage of the disease, nodal status, tumor status, and performance status, inasmuch as the worse each above-mentioned variable became, the higher the median and interquartile serum marker level was. Neither CYFRA 21-1 nor TPS was able to accurately discriminate between stage IIIa (marginally resectable) and stage IIIb (unresectable) non-small-cell lung cancers, however. In both small-cell and non-small-cell lung cancers, univariate survival analyses demonstrated that either a CYFRA 21-1 level over 3.6 ng/ml or a TPS level over 140 U/L significantly indicated a poor survival rate. In the whole population, taking into account other significant variables, Cox's model analysis demonstrated that a poor performance index, an advanced stage of the disease, the presence of metastases, elevated serum lactate dehydrogenase, and high serum CYFRA 21-1 (odds ratio, 1.74; 95% confidence interval, [1.33-2.27] were independent prognostic variables. We concluded that CYFRA 21-1 is a significant determinant of survival. Other applications of cytokeratin markers in lung cancer are still limited.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
154
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
725-33
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8810612-Adult,
pubmed-meshheading:8810612-Aged,
pubmed-meshheading:8810612-Aged, 80 and over,
pubmed-meshheading:8810612-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8810612-Carcinoma, Small Cell,
pubmed-meshheading:8810612-Female,
pubmed-meshheading:8810612-Humans,
pubmed-meshheading:8810612-Keratins,
pubmed-meshheading:8810612-Lung Diseases,
pubmed-meshheading:8810612-Lung Neoplasms,
pubmed-meshheading:8810612-Male,
pubmed-meshheading:8810612-Middle Aged,
pubmed-meshheading:8810612-Peptides,
pubmed-meshheading:8810612-Prognosis,
pubmed-meshheading:8810612-Prospective Studies,
pubmed-meshheading:8810612-Sensitivity and Specificity,
pubmed-meshheading:8810612-Tissue Polypeptide Antigen,
pubmed-meshheading:8810612-Tumor Markers, Biological
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
|
| pubmed:affiliation |
Department of Chest Diseases, Hôpital Arnaud de Villeneuve, Montpellier, France.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|